{"id":"tp-28323","type":"article-newspaper","title":"Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral on Danon Disease Therapy","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/28323","datePublished":"2026-10-08T16:47:32.000Z","dateModified":"2026-10-08T16:47:32.000Z","language":"en","abstract":"The bank raised its rating from Sell after updates on RP-A501, Rocket Pharmaceuticals’ experimental treatment for the rare disorder Danon disease.","section":"Investing","references":[]}